1. South Korea Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Samil Pharmaceutical Co.,Ltd

Samil Pharmaceutical Co.,Ltd

000520.KS
Samil Pharmaceutical Co.,LtdKR flagKorea Exchange
6,430.00
KRW
-110.00
- -
137.41BMarket Cap

Total Valuation

Samil Pharmaceutical Co.,Ltd carries a market capitalization of 137.41B, placing it among publicly traded companies globally. Its enterprise value stands at 360.32B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap137.41B
Enterprise Value360.32B

Share Statistics

Samil Pharmaceutical Co.,Ltd currently has 21.23M shares outstanding.

Shares Outstanding21.23M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

The price-to-sales ratio is 0.93, and the price-to-book ratio stands at -11.97.

PE RatioN/A
PS Ratio0.93
PB Ratio-11.97
P/TBV Ratio1.59
P/FCF Ratio9.16
P/OCF Ratio17.71

Enterprise Valuation

EV / Sales1.71
EV / EBITDAN/A
EV / EBITN/A
EV / FCF12.25

Financial Position

Samil Pharmaceutical Co.,Ltd maintains a current ratio of 0.46, meaning it holds 0.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 129.15, indicating elevated leverage, while an interest coverage ratio of -2.89 demonstrates limited ability to service its debt obligations.

Current Ratio0.46
Quick Ratio0.01
Debt / Equity129.15
Debt / EBITDA-6.59
Interest Coverage-2.89

Financial Efficiency

Return on Equity (ROE)-535.62
Return on Assets (ROA)-9.48
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)N/A
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover3.73

Taxes

Income Tax-2.82B
Effective Tax RateN/A

Stock Price Statistics

Samil Pharmaceutical Co.,Ltd's stock has declined approximately -37.45136% over the past 52 weeks. The 50-day moving average sits at 7,723.00, while the 200-day moving average is 9,500.65.

Beta (5Y)N/A
52-Week Price Change-37.45136%
50-Day Moving Average7,723.00
200-Day Moving Average9,500.65
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Samil Pharmaceutical Co.,Ltd generated 210.51B in revenue and converted that into -36.42B in net income, yielding earnings per share of -1,713.89. EBITDA reached -25.21B, while operating income came in at -25.21B.

Revenue210.51B
Gross Profit75.75B
Operating Income-25.21B
Pretax Income-39.24B
Net Income-36.42B
EBITDA-25.21B
EBIT-25.21B
Earnings Per Share (EPS)-1,713.89

Balance Sheet

Samil Pharmaceutical Co.,Ltd holds 1.19B in cash and equivalents against 166.03B in total debt, resulting in a net debt position of 162.70B. Total book value stands at -16.33B, with working capital of -89.00B providing operational flexibility.

Cash & Cash Equivalents1.19B
Total Debt166.03B
Net Debt162.70B
Equity (Book Value)-16.33B
Book Value Per Share-768.61
Working Capital-89.00B

Cash Flow

Samil Pharmaceutical Co.,Ltd produced 11.04B in operating cash flow over the past twelve months. After subtracting -10.30B in capital expenditures, free cash flow totaled 741.70M - equivalent to 34.91 per share.

Operating Cash Flow11.04B
Capital Expenditures-10.30B
Free Cash Flow741.70M
FCF Per Share34.91

Margins

Samil Pharmaceutical Co.,Ltd operates with a gross margin of 35.98, reflecting its pricing power and cost economics. The operating margin of -11.98 and net profit margin of -17.30 provide insight into operational efficiency.

Gross Margin35.98
Operating Margin-11.98
Pretax Margin-18.64
Profit Margin-17.30
EBITDA Margin-11.98

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield-0.10
FCF Yield10.92

Stock Splits

Samil Pharmaceutical Co.,Ltd's most recent stock split took place on March 24, 2023 with a 10:11 split ratio.

Last Split Date3/24/2023
Split Ratio10:11

Scores

Samil Pharmaceutical Co.,Ltd posts an Altman Z-Score of 0.43, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score0.43